HIV

A new grant advances a strategy to durably lock HIV in its dormant state inside cells.

The Campbell Foundation funded the project because it tackles a major barrier to durable HIV therapies.

An FDA‑approved medication called spironolactone, often prescribed as a diuretic, or water pill, for heart and blood pressure conditions, may be a useful add‑on to the standard HIV treatment, a new study shows.

"These grants highlight The Wertheim UF Scripps Institute’s unique expertise in areas that include neuroscience, immunology, biochemistry, drug discovery and RNA therapeutics,” said Scientific Director Patrick Griffin, Ph.D.

A new study in Nature that finds a gene therapy against HIV given at birth can protect breastfeeding babies from infection with a single dose.

The protein called p32 might provide a potential target for drugs that keep HIV dormant and harmless. It was discovered by Susana Valente, Ph.D.

The scientists have devised a way to lock HIV in its dormant stage. Now they want to throw away the key.